BKT140

BKT140, also known as 4F-benzoyl-TN14003, is a synthetic peptide designed as a potent and selective antagonist of the chemokine receptor CXCR4. As a member of the peptide compound class, it is structurally engineered to mimic and modulate natural chemokine interactions, offering valuable utility in the study of receptor-ligand dynamics within the chemokine signaling axis. Its high affinity and specificity for CXCR4 make it a critical tool for dissecting the roles of this receptor in various cellular processes, particularly those related to cell migration, immune cell trafficking, and signal transduction. BKT140's unique characteristics have positioned it as a preferred research reagent in fields investigating chemokine receptor biology and the molecular mechanisms underlying cell movement and localization.

Receptor Antagonism Studies: In receptor pharmacology research, BKT140 is widely employed to investigate CXCR4-mediated signaling pathways. By competitively inhibiting the binding of endogenous ligands such as stromal cell-derived factor-1 (SDF-1 or CXCL12), it enables researchers to delineate the downstream effects of CXCR4 activation or blockade. This selective antagonism is instrumental for mapping receptor-specific responses in diverse cell types, providing a robust experimental approach for elucidating the physiological and pathological functions of chemokine receptors.

Cell Migration and Homing Assays: The compound finds extensive application in studies focused on cell migration, chemotaxis, and homing, particularly in hematopoietic and immune cell populations. By blocking CXCR4, BKT140 allows for precise evaluation of the receptor's role in directing cell movement in response to chemokine gradients. This is especially valuable in transwell migration assays, in vitro chemotaxis models, and in vivo tracking studies, where understanding the mechanisms of cell trafficking is essential for advancing knowledge in immunology and developmental biology.

Peptide Structure-Activity Relationship (SAR) Research: As an optimized peptide antagonist, BKT140 serves as a reference molecule in structure-activity relationship investigations. Researchers utilize it to compare the effects of specific amino acid substitutions or backbone modifications on receptor binding and functional inhibition. Insights gained from such comparative analyses contribute to the rational design of next-generation CXCR4 modulators and enhance understanding of the molecular determinants governing peptide-receptor interactions.

Signal Transduction Analysis: In cellular signaling studies, BKT140 is used to probe the intricate web of downstream pathways activated by CXCR4 engagement. By selectively blocking receptor activation, it facilitates the identification of signaling cascades, gene expression changes, and protein modifications that are contingent upon chemokine receptor input. This targeted approach aids in unraveling the complex networks that regulate cell fate decisions, survival, and proliferation in various biological contexts.

Preclinical Model Development: The compound is also utilized in the development of preclinical experimental models to study the impact of CXCR4 inhibition on disease-relevant processes. By incorporating BKT140 into in vitro and in vivo systems, researchers can mimic conditions of chemokine receptor blockade, enabling the exploration of CXCR4's role in pathological states such as inflammation, tissue remodeling, and aberrant cell migration. These models are essential for generating mechanistic insights and validating hypotheses regarding chemokine axis function in health and disease.

1. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

2. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics